Avinger To Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15

Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR), a medical device company, will engage in investor meetings from September 13-15, 2021, at the H.C. Wainwright 23rd Annual Global Investment Conference. The company specializes in the diagnosis and treatment of Peripheral Artery Disease (PAD), which impacts over 12 million people in the U.S. and 200 million globally. Avinger is known for its innovative Lumivascular platform, including its imaging console and catheter systems. Interested investors can contact H.C. Wainwright for scheduling inquiries.

REDWOOD CITY, CA / ACCESSWIRE / September 8, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its management will participate in investor meetings September 13-15, 2021 as part of the H.C. Wainwright 23rd Annual Global Investment Conference.

Institutional investors that wish to schedule a meeting with management can contact their H.C. Wainwright sales representative or Matt Kreps, Investor Relations for Avinger, at mkreps@darrowir.com.

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye™ family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Follow Avinger on Twitter and Facebook.

Investor Contact:

Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

SOURCE: Avinger, Inc.

View source version on accesswire.com:
https://www.accesswire.com/662978/Avinger-To-Present-at-the-HC-Wainwright-23rd-Annual-Global-Investment-Conference-September-13-15

FAQ

What is Avinger, Inc. known for?

Avinger, Inc. is known for developing the first and only intravascular image-guided, catheter-based system for diagnosing and treating Peripheral Artery Disease (PAD).

When will Avinger participate in the H.C. Wainwright Global Investment Conference?

Avinger will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

How can investors schedule a meeting with Avinger's management?

Investors can schedule a meeting with Avinger's management by contacting their H.C. Wainwright sales representative or Matt Kreps at investor relations.

What is the estimated effect of Peripheral Artery Disease (PAD) globally?

Peripheral Artery Disease (PAD) is estimated to affect over 200 million people worldwide.

What products does Avinger offer for PAD treatment?

Avinger offers the Lumivascular platform, which includes the Lightbox imaging console and a range of chronic total occlusion catheters and atherectomy devices.